There will be many more people doing this sort of thing in the years ahead. The main reason not to do it now for those genetic alterations known to exist in hu

There will be many more people doing this sort of thing in the years ahead. The main reason not to do it now for those genetic alterations known to exist in humans and have beneficial efforts, or to address genetic disease, would be that presently available approaches do not have reliable, high degrees of transfection. The cell coverage is low. That is being solved. The work on gene therapy for muscular dystrophy is one line of research to watch as a marker of progress on this front. As soon as reliable, high-enough levels of transfection are a reality, there will be a lot of unofficial gene therapy going on. The FDA and other regulators impose enormous cost and delay, as well as removing the agency of patients and those who desire enhancement rather than therapy. They will be bypassed, just as they were bypassed for stem cell therapies.